Clinical Trial

WL276 CAR-T Cell Therapy for CD276 Positive Recurrent or Progressive Glioblastoma Patients

Name: WL276 CAR-T Cell Therapy for CD276 Positive Recurrent or Progressive Glioblastoma Patients — clinical trial record (NCT06691308)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Early Phase 1

View on ClinicalTrials.gov →

Summary

Clinical study evaluating the safety and efficacy of WL276 CAR-T cell therapy in CD276 positive recurrent or progressive glioblastoma patients

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2024-11-13.

Trial Details

NCT Number	NCT06691308
Lead Sponsor	Beijing Immunochina Medical Science & Technology Co., Ltd.
Conditions	Recurrent or Progressive Glioblastoma
Enrollment	6 participants
Start Date	2024-11-12
Primary Completion	2027-05-31 (estimated)
Study Completion	2027-05-31 (estimated)
Updated on ClinicalTrials.gov	2024-11-18